KR100872042B1 - 마이오스타틴을 발현하는 세포표면 발현벡터 및 상기벡터에 의해 형질전환된 미생물 - Google Patents
마이오스타틴을 발현하는 세포표면 발현벡터 및 상기벡터에 의해 형질전환된 미생물 Download PDFInfo
- Publication number
- KR100872042B1 KR100872042B1 KR1020060088995A KR20060088995A KR100872042B1 KR 100872042 B1 KR100872042 B1 KR 100872042B1 KR 1020060088995 A KR1020060088995 A KR 1020060088995A KR 20060088995 A KR20060088995 A KR 20060088995A KR 100872042 B1 KR100872042 B1 KR 100872042B1
- Authority
- KR
- South Korea
- Prior art keywords
- myostatin
- pgsa
- mature protein
- microorganism
- protein
- Prior art date
Links
- 108010056852 Myostatin Proteins 0.000 title claims abstract description 145
- 244000005700 microbiome Species 0.000 title claims abstract description 48
- 210000004027 cell Anatomy 0.000 title claims abstract description 43
- 239000013604 expression vector Substances 0.000 title claims abstract description 37
- 102000004472 Myostatin Human genes 0.000 title claims abstract 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 145
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 118
- 229960005486 vaccine Drugs 0.000 claims abstract description 27
- 239000002253 acid Substances 0.000 claims abstract description 18
- 210000003205 muscle Anatomy 0.000 claims abstract description 17
- 239000003674 animal food additive Substances 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 238000012258 culturing Methods 0.000 claims abstract description 7
- 201000006938 muscular dystrophy Diseases 0.000 claims abstract description 7
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 6
- 239000002157 polynucleotide Substances 0.000 claims abstract description 6
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 6
- 238000011282 treatment Methods 0.000 claims abstract description 6
- 244000144977 poultry Species 0.000 claims abstract description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 64
- 101150076330 pgsA gene Proteins 0.000 claims description 43
- 101100059000 Bacillus subtilis (strain 168) capA gene Proteins 0.000 claims description 40
- 101100083407 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) pgsA1 gene Proteins 0.000 claims description 40
- 241000894006 Bacteria Species 0.000 claims description 38
- 241000186660 Lactobacillus Species 0.000 claims description 35
- 239000004310 lactic acid Substances 0.000 claims description 33
- 235000014655 lactic acid Nutrition 0.000 claims description 32
- 229940039696 lactobacillus Drugs 0.000 claims description 31
- 241001465754 Metazoa Species 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 22
- 230000037396 body weight Effects 0.000 claims description 13
- 230000001965 increasing effect Effects 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 210000000663 muscle cell Anatomy 0.000 claims description 10
- 230000035800 maturation Effects 0.000 claims description 9
- 241000282412 Homo Species 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 8
- 241000251468 Actinopterygii Species 0.000 claims description 7
- 210000000577 adipose tissue Anatomy 0.000 claims description 6
- 230000037257 muscle growth Effects 0.000 claims description 5
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 241000282414 Homo sapiens Species 0.000 claims description 4
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims description 3
- 241000607768 Shigella Species 0.000 claims description 3
- 101100059011 Bacillus subtilis (strain 168) capB gene Proteins 0.000 claims description 2
- 101100219452 Bacillus subtilis (strain 168) capC gene Proteins 0.000 claims description 2
- 241000186779 Listeria monocytogenes Species 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 241000186366 Mycobacterium bovis Species 0.000 claims description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 2
- 241000607626 Vibrio cholerae Species 0.000 claims description 2
- 101150103033 lpxB gene Proteins 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 241000595586 Coryne Species 0.000 claims 1
- 239000013598 vector Substances 0.000 abstract description 44
- 230000000694 effects Effects 0.000 abstract description 20
- 201000000585 muscular atrophy Diseases 0.000 abstract description 8
- 206010028289 Muscle atrophy Diseases 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 244000144972 livestock Species 0.000 abstract description 4
- 230000033228 biological regulation Effects 0.000 abstract description 3
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000009261 transgenic effect Effects 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 125
- 235000018102 proteins Nutrition 0.000 description 106
- 244000199866 Lactobacillus casei Species 0.000 description 20
- 235000013958 Lactobacillus casei Nutrition 0.000 description 19
- 229940017800 lactobacillus casei Drugs 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 18
- 108010052285 Membrane Proteins Proteins 0.000 description 14
- 108090000637 alpha-Amylases Proteins 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 12
- 102000004139 alpha-Amylases Human genes 0.000 description 12
- 229940024171 alpha-amylase Drugs 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 102000037865 fusion proteins Human genes 0.000 description 11
- 108020001507 fusion proteins Proteins 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 102000018697 Membrane Proteins Human genes 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 101000886557 Gallus gallus Growth/differentiation factor 8 Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000282887 Suidae Species 0.000 description 7
- 230000001488 breeding effect Effects 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 241000287828 Gallus gallus Species 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 235000019688 fish Nutrition 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 5
- 101000886576 Bos taurus Growth/differentiation factor 8 Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 241000192125 Firmicutes Species 0.000 description 5
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 5
- 238000009395 breeding Methods 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 210000002421 cell wall Anatomy 0.000 description 5
- 235000013330 chicken meat Nutrition 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 210000001087 myotubule Anatomy 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- 239000004382 Amylase Substances 0.000 description 4
- 241000972773 Aulopiformes Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 235000019515 salmon Nutrition 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 102000018997 Growth Hormone Human genes 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000019730 animal feed additive Nutrition 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- BOFRXDMCQRTGII-UHFFFAOYSA-N 619-08-9 Chemical compound OC1=CC=C([N+]([O-])=O)C=C1Cl BOFRXDMCQRTGII-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 244000037364 Cinnamomum aromaticum Species 0.000 description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 101100082540 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) pcp gene Proteins 0.000 description 2
- 208000029578 Muscle disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 101710178358 Peptidoglycan-associated lipoprotein Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 101001075131 Sus scrofa Growth/differentiation factor 8 Proteins 0.000 description 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003630 growth substance Substances 0.000 description 2
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 101150074251 lpp gene Proteins 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000004096 skeletal muscle tissue growth Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- -1 2-chloro-4-nitrophenyl Chemical group 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 102100027153 Ankyrin repeat and sterile alpha motif domain-containing protein 1B Human genes 0.000 description 1
- 101710149294 Ankyrin repeat and sterile alpha motif domain-containing protein 1B Proteins 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108700025208 Bacillus subtilis CotB Proteins 0.000 description 1
- 235000000853 Bacillus subtilis subsp chungkookjang Nutrition 0.000 description 1
- 244000192971 Bacillus subtilis subsp chungkookjang Species 0.000 description 1
- 108700029181 Bacteria lipase activator Proteins 0.000 description 1
- 101710168515 Cell surface glycoprotein Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 108010092442 Escherichia coli Adhesins Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 108010002231 IgA-specific serine endopeptidase Proteins 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- 241000277329 Oncorhynchus keta Species 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 241001442654 Percnon planissimum Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101710099182 S-layer protein Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000007994 TES buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000010429 evolutionary process Effects 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 108010063679 ice nucleation protein Proteins 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000004020 intracellular membrane Anatomy 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940126578 oral vaccine Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000027086 plasmid maintenance Effects 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005892 protein maturation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 101150076332 slpA gene Proteins 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (15)
- 폴리감마글루탐산 합성효소 복합체를 코딩하는 유전자 pgsB, pgsC 및 pgsA로 구성된 군에서 선택되는 어느 하나 이상과, 서열번호 11 내지 서열번호 14 중 어느 하나의 서열로 표시되는 마이오스타틴 단백질의 성숙(mature) 도메인을 코딩하는 폴리뉴클레오티드를 함유하는 세포표면 발현벡터.
- 제1항에 있어서, 상기 마이오스타틴은 포유동물, 조류(가금류) 또는 어류 유래인 것을 특징으로 하는 발현벡터.
- 제1항에 있어서, 상기 표면 발현벡터는 SlpA7 프로모터를 함유하는 것을 특징으로 하는 발현벡터.
- 제1항에 있어서, pBT:pgsA-CMyom, pBT:pgsA-PMyom, pBT:pgsA-BMyom 및 pBT:pgsA-FMyom으로 구성된 군에서 선택된 어느 하나인 것을 특징으로 하는 발현벡터.
- 제1항 내지 제4항 중 어느 한 항의 발현벡터로 형질전환된 미생물.
- 제5항에 있어서, 상기 미생물은 대장균, 살모넬라 타이피, 살모넬라 타이피뮤리움, 비브리오 콜레라, 마이코박테리움 보비스, 시겔라, 바실러스, 유산균, 스테필로코커스, 코리네 박테리아, 리스테리아 모노싸이토제네스 및 스트랩토코커스로 이루어지는 군에서 선택된 어느 하나인 것을 특징으로 하는 형질전환된 미생물.
- 제5항에 있어서, 상기 미생물은 유산균인 것을 특징으로 하는 형질전환된 미생물.
- 제5항의 형질전환된 미생물을 배양하여 마이오스타틴 성숙(mature) 단백질을 미생물 표면에 발현하는 단계; 및 상기 마이오스타틴 성숙 단백질이 표면발현된 미생물을 회수하는 단계를 포함하는 마이오스타틴 성숙(mature) 단백질이 표면발현된 미생물을 제조하는 방법.
- 제8항의 방법에 의해 제조된 마이오스타틴 성숙(mature) 단백질이 표면발현된 미생물을 유효성분으로 함유하는 인간을 제외한 동물의 근육성장 촉진 및 증체율 향상용 사료첨가제.
- 제8항의 방법에 의해 제조된 세포표면에 발현된 마이오스타틴 성숙(mature) 단백질을 유효항원으로 함유하는 근이영양증 또는 근육위축증의 예방 또는 치료용 백신.
- 제10항에 있어서, 경구용 또는 식용섭취가 가능한 것을 특징으로 하는 백신.
- 제9항의 사료첨가제를 동물에 급여하는 것을 특징으로 하는 인간을 제외한 동물의 체중, 근육질, 근육세포수 또는 근육세포 크기를 증가시키거나, 체지방량을 감소시키는 방법.
- 제10항의 백신을 동물에 투여하는 것을 특징으로 하는 인간을 제외한 동물의 체중, 근육질, 근육세포수 또는 근육세포 크기를 증가시키거나, 체지방량을 감소시키는 방법.
- 삭제
- 삭제
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060088995A KR100872042B1 (ko) | 2005-09-14 | 2006-09-14 | 마이오스타틴을 발현하는 세포표면 발현벡터 및 상기벡터에 의해 형질전환된 미생물 |
PCT/KR2007/000856 WO2008032911A1 (en) | 2006-09-14 | 2007-02-16 | Cell surface expression vector of myosyatin and microorganisms transformed therewith |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050085543 | 2005-09-14 | ||
KR1020060088995A KR100872042B1 (ko) | 2005-09-14 | 2006-09-14 | 마이오스타틴을 발현하는 세포표면 발현벡터 및 상기벡터에 의해 형질전환된 미생물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070031248A KR20070031248A (ko) | 2007-03-19 |
KR100872042B1 true KR100872042B1 (ko) | 2008-12-05 |
Family
ID=39183938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060088995A KR100872042B1 (ko) | 2005-09-14 | 2006-09-14 | 마이오스타틴을 발현하는 세포표면 발현벡터 및 상기벡터에 의해 형질전환된 미생물 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR100872042B1 (ko) |
WO (1) | WO2008032911A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010079991A2 (ko) | 2009-01-08 | 2010-07-15 | 주식회사 바이오리더스 | 안정적인 항시적 고발현 자궁경부암 치료백신용 벡터 및 그에 의해 형질전환된 재조합 유산균 |
US9228190B2 (en) | 2009-01-08 | 2016-01-05 | Bioleaders Corporation | Vector for constitutive high-level expression containing REPe mutant gene |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100923664B1 (ko) * | 2007-09-21 | 2009-10-28 | 대한민국(관리부서 : 농림수산식품부 국립수의과학검역원) | 돼지 IgG의 Fc 도메인의 세포 표면 발현용 벡터, 상기 벡터에 의해 형질전환된 숙주세포, 상기 숙주세포를 이용한 돼지 질병 관련 바이러스 백신 및 이의 제조방법 |
KR100857861B1 (ko) * | 2007-10-15 | 2008-09-11 | 주식회사 바이오리더스 | Myo-2 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물 |
KR101030792B1 (ko) * | 2010-09-16 | 2011-04-27 | 주식회사 코미팜 | 돼지 써코바이러스2(pcv2) 유전자의 표면발현용 벡터 및 이로 형질전환된 살모넬라 백신 균주 |
CN113679827A (zh) * | 2021-08-02 | 2021-11-23 | 华南农业大学 | 一种基于斜带石斑鱼mstn自体基因疫苗的构建方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1072680A1 (en) | 1999-07-30 | 2001-01-31 | Pfizer Products Inc. | Myostatin regulatory region, nucleotide sequence determination and methods for its use |
KR100469936B1 (ko) | 2003-06-04 | 2005-02-03 | 주식회사 바이오리더스 | 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU756620B2 (en) * | 1997-07-14 | 2003-01-16 | University Of Liege | Mutations in the myostation gene cause double-muscling in mammals |
ATE342990T1 (de) * | 2001-08-10 | 2006-11-15 | Bioleaders Corp | Oberflächenexpressionsvektoren mit pgsbca, dem für poly-gamma-glutamat-synthetase codierenden gen, sowie verfahren zur expression eines zielproteins an der oberfläche eines den vektor benutzenden mikroorganismus |
-
2006
- 2006-09-14 KR KR1020060088995A patent/KR100872042B1/ko active IP Right Grant
-
2007
- 2007-02-16 WO PCT/KR2007/000856 patent/WO2008032911A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1072680A1 (en) | 1999-07-30 | 2001-01-31 | Pfizer Products Inc. | Myostatin regulatory region, nucleotide sequence determination and methods for its use |
KR100469936B1 (ko) | 2003-06-04 | 2005-02-03 | 주식회사 바이오리더스 | 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010079991A2 (ko) | 2009-01-08 | 2010-07-15 | 주식회사 바이오리더스 | 안정적인 항시적 고발현 자궁경부암 치료백신용 벡터 및 그에 의해 형질전환된 재조합 유산균 |
US8685721B2 (en) | 2009-01-08 | 2014-04-01 | Bioleaders Corporation | Stable constitutively high expression vector for preparing HPV vaccine and recombinant lactic acid bacteria transformed thereby |
US9228190B2 (en) | 2009-01-08 | 2016-01-05 | Bioleaders Corporation | Vector for constitutive high-level expression containing REPe mutant gene |
Also Published As
Publication number | Publication date |
---|---|
WO2008032911A1 (en) | 2008-03-20 |
KR20070031248A (ko) | 2007-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Medaglini et al. | Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization. | |
Schulz et al. | Disruption of the guanylyl cyclase-C gene leads to a paradoxical phenotype of viable but heat-stable enterotoxin-resistant mice. | |
KR100872042B1 (ko) | 마이오스타틴을 발현하는 세포표면 발현벡터 및 상기벡터에 의해 형질전환된 미생물 | |
CN101969990B (zh) | 增强针对艾美球虫属的免疫反应的组合物和方法 | |
KR20210133888A (ko) | 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물 | |
KR20040032824A (ko) | 바실러스 속 균주 유래의 폴리감마글루탐산 합성유전자를이용한 표면 발현용 벡터 및 이를 이용한 단백질의 미생물표면 발현 방법 | |
KR100578395B1 (ko) | 면역기능이 강화된 사균화 유산균 제제 및 그 제조방법 | |
AU2024201593A1 (en) | A genetically modified Lactobacillus and uses thereof | |
KR20040104936A (ko) | 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물 | |
KR100857861B1 (ko) | Myo-2 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물 | |
US6545198B1 (en) | Transgenically produced prolactin | |
JP2021137021A (ja) | 遺伝子発現カセット及びそれを含む発現ベクター | |
EA017633B1 (ru) | Пептиды, увеличивающие продукцию бактериоцинов, способы увеличения продукции бактериоцинов и выделенные бактериоцины | |
Havenith et al. | Gut-associated lactobacilli for oral immunisation | |
TWI241407B (en) | Live attenuated bacteria of the species actinobacillus pleuropneumoniae | |
KR100782332B1 (ko) | 새우 흰 반점 바이러스 항원의 표면 발현벡터 및 이에 의해형질전환된 미생물 | |
KR100720755B1 (ko) | 파보바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물 | |
KR100985914B1 (ko) | 간암 특이 항원인 알파페토단백질의 표면발현벡터 및 이에의해 형질전환된 미생물 | |
EP0645454A2 (en) | Chimeric somatostatin containing protein and coding DNA, immunogenic compositions and method for increasing farm animal productivity | |
US7807144B2 (en) | Oral vaccines | |
WO2003020040A1 (en) | Oral vaccines | |
KR101263099B1 (ko) | 돼지 대장균 설사증에 대한 백신 조성물 | |
WO2010005273A2 (ko) | 인간 락토페린을 대량생산하기 위한 형질전환 제브라피쉬 및 이를 이용한 인간 락토페린의 대량생산방법 | |
KR100465347B1 (ko) | 효모에서 악티노바실러스 플루로뉴모니애의 재조합ApxⅡA 독소 단백질을 제조하는 방법 및사료첨가제로서의 이의 용도 | |
CN1333077C (zh) | 缩胆囊素活性片段的串联表达及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121129 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20131129 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20141201 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20151127 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20161129 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20171103 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20181102 Year of fee payment: 11 |